Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy - Archive ouverte HAL
Article Dans Une Revue Annals of Oncology Année : 2022

Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy

Dates et versions

hal-03940635 , version 1 (16-01-2023)

Identifiants

Citer

Younes Belkouchi, Hugues Talbot, Nathalie Lassau, L. Lawrance, S. Farhane, et al.. Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy. Annals of Oncology, 2022, 33, pp.S595-S596. ⟨10.1016/j.annonc.2022.07.159⟩. ⟨hal-03940635⟩
105 Consultations
0 Téléchargements

Altmetric

Partager

More